Loading…
Century Therapeutics, Inc. is projected to rise to $2.17 by 2027, a +7% move from its current price of $2.02. IPSC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.96 | $2.02 | $2.09 | +0.04% |
| Aug 4 | $1.93 | $2.02 | $2.12 | +0.08% |
| Aug 5 | $1.91 | $2.02 | $2.14 | +0.12% |
| Aug 6 | $1.89 | $2.02 | $2.16 | +0.16% |
| Aug 7 | $1.88 | $2.02 | $2.18 | +0.19% |
| Aug 8 | $1.87 | $2.02 | $2.19 | +0.23% |
| Aug 9 | $1.86 | $2.03 | $2.21 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.86 | $2.03 | $2.21 | +0.27% |
| Week 2 | $1.80 | $2.03 | $2.30 | +0.55% |
| Week 3 | $1.75 | $2.04 | $2.37 | +0.82% |
| Week 4 | $1.72 | $2.04 | $2.43 | +1.10% |
| Week 5 | $1.69 | $2.05 | $2.49 | +1.37% |
| Week 6 | $1.66 | $2.05 | $2.54 | +1.65% |
| Week 7 | $1.64 | $2.06 | $2.59 | +1.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Century Therapeutics, Inc. is a biotechnology company that engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product CNTY-813 is an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
The company is also involved in CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Century Therapeutics, Inc. (IPSC) is a biotechnology company focused on allogeneic cell therapies. The stock is currently priced at $2.17 per share with a market capitalization of $391.37M and a market ranking of 3259.
The current price sits at $2.17, and the market cap is $391.37M, with IPSC ranking 3259 by market capitalization. The overall price outlook indicates a path of continued movement through 2026 with a neutral stance, followed by stronger upside in the later multi-year horizon.
Forecast data for 2026 show an average price of $2.17 with a neutral sentiment, and the multi-year outlook advances into bullish territory from 2030 onward, with notable upside projected for 2030, 2040, and 2050.
A major floor 14.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 21.3% above — a clean break opens room to run.
A major ceiling 28.7% above — clearing it would confirm fresh momentum.
Key IPSC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IPSC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.07 | Sell | $2.08 | Sell |
| MA 10 | $2.12 | Sell | $2.12 | Sell |
| MA 20 | $2.20 | Sell | $2.17 | Sell |
| MA 50 | $2.24 | Sell | $2.22 | Sell |
| MA 100 | $2.28 | Sell | $2.15 | Sell |
| MA 200 | $1.76 | Buy | $1.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.69 | Neutral |
| Stoch RSI (14) | 30.40 | Neutral |
| CCI (20) | -134.55 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -6.91 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 38.86 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 2.06 | Sell |
| ADX (14) | 11.78 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) is 40.
Near-term momentum is guided by the 50-day and 200-day moving averages, with SMA50 at $2.28 and SMA200 at $1.67. Support is at $2.07 and resistance at $2.45, framing a modest trading band. The 30-day range spans from a low of $1.79 to a high of $2.63, underscoring the current muted directional bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.90 | $2.02 | $2.58 | 0% | Neutral | |
| $1.70 | $2.17 | $2.95 | +7% | Neutral | |
| $1.71 | $2.27 | $3.22 | +12% | Neutral | |
| $1.61 | $2.19 | $3.22 | +8% | Neutral | |
| $1.85 | $2.59 | $3.91 | +28% | Bullish | |
| $2.14 | $3.06 | $4.75 | +52% | Bullish | |
| $2.29 | $3.35 | $5.31 | +66% | Bullish | |
| $2.49 | $3.71 | $6.00 | +84% | Bullish | |
| $2.21 | $3.36 | $5.53 | +66% | Bullish | |
| $2.19 | $3.39 | $5.68 | +68% | Bullish | |
| $3.04 | $5.14 | $9.23 | +154% | Bullish | |
| $5.47 | $10.78 | $21.43 | +434% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.90 | $2.02 | $2.42 | +0.00% |
| September 2026 | $1.74 | $2.07 | $2.54 | +2.60% |
| October 2026 | $1.74 | $2.09 | $2.60 | +0.99% |
| November 2026 | $1.68 | $2.03 | $2.55 | -3.16% |
| December 2026 | $1.67 | $2.03 | $2.58 | +0.24% |
Click any year to see its month-by-month IPSC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Century Therapeutics, Inc.'s 2026 outlook centres on $2.02, within a $0.90 to $2.58 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, IPSC could reach as high as $2.95, with a base case around $2.17 and support toward $1.70 — roughly +7% from $2.02. A consolidation phase looks the most probable path here.
Expect IPSC to range from $1.71 to $3.22 through 2028. The $2.27 average target implies a +12% move from current prices. That is up +5% on the projected 2027 average. Price action looks broadly range-bound.
The IPSC price prediction for 2029 points to an average of $2.19 (low $1.61, high $3.22) — a potential gain of +8% on today's $2.02. A consolidation phase looks the most probable path here.
In 2030, IPSC is projected to trade between $1.85 and $3.91, averaging $2.59 — a potential gain of +28% from today's $2.02. That is up +18% on the projected 2029 average. Momentum favours further upside here.
Century Therapeutics, Inc.'s 2031 outlook centres on $3.06, within a $2.14 to $4.75 range. That is up +18% on the projected 2030 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, IPSC could reach as high as $5.31, with a base case around $3.35 and support toward $2.29 — roughly +66% from $2.02. Momentum favours further upside here.
Expect IPSC to range from $2.49 to $6.00 through 2033. The $3.71 average target implies a +84% move from current prices. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The IPSC price prediction for 2034 points to an average of $3.36 (low $2.21, high $5.53) — a potential gain of +66% on today's $2.02. Momentum favours further upside here.
In 2035, IPSC is projected to trade between $2.19 and $5.68, averaging $3.39 — a potential gain of +68% from today's $2.02. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Century Therapeutics, Inc.'s 2040 outlook centres on $5.14, within a $3.04 to $9.23 range. That is up +51% on the projected 2035 average. That marks a +154% change versus current levels. Momentum favours further upside here.
By 2050, IPSC could reach as high as $21.43, with a base case around $10.78 and support toward $5.47 — roughly +434% from $2.02. Buyers look set to stay in control over this stretch.
Investing $1,000 in IPSC today (≈ 495.049505 IPSC) could be worth
$5,335.42
+$4,335.42 (+434%) by 2050 · US Dollar
Based on the average projected IPSC price of $10.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IPSCwould be worth at today's price.
$1,000 invested in IPSC on Jul 31, 2025 (≈ 1,824.817591 IPSC) would be worth
$3,686.13
+$2,686.13 (+268.6%) today · 3.69× · US Dollar
Based on a IPSC entry price of $0.548 vs. today's $2.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.11 | $957.35 | -4.3% |
| 1 month ago | $2.39 | $845.19 | -15.5% |
| 3 months ago | $2.31 | $874.46 | -12.6% |
| 6 months ago | $1.84 | $1,097.83 | +9.8% |
| 1 year ago | $0.548 | $3,686.13 | +268.6% |
| All time (5.0y) ago | $29.71 | $67.99 | -93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IPSC forecast.
Our base-case forecast reaches $4.00 around 2040.
Implied market cap at $4.00: $721.42M
The multi-year outlook shows substantial upside beyond 2026. In 2030, the average price is projected at $2.76 with a min of $2.03 and a max of $4.07, representing a 27.3% ROI and a bullish sentiment. The forecast also points to continued strength into 2031-2035 with annualized gains and bullish sentiment, culminating in 2040 where the average price is $5.47 and the max $9.43, a 152.3% ROI.
By 2050, the average price is projected to $11.57 with a max of $21.89, representing a 433.3% ROI and a bullish sentiment. These figures illustrate a clear long-run upward trajectory, though they remain estimates and are not guaranteed. The path is anchored by the asset’s ongoing development of CNTY-813, CNTY-308, and CNTY-101 programs, but outcomes depend on factors not provided here.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $2.76 with a min of $2.03 and a max of $4.07, and an estimated 27.3% ROI. The sentiment is BULLISH.
The forecast depicts a path from a neutral near term to bullish longer term, with 2030 average of $2.76 and rising to $5.47 by 2040 and $11.57 by 2050, yielding potential upside (e.g., 27.3% ROI in 2030 and 433.3% by 2050). These are estimates, not guarantees.
The 2040 max is $9.43, but by 2050 the max is $21.89, so reaching $10 is within the upper end of the 2050 forecast.
The current price is $2.17 and the market cap is $391.37M.
The near-term technical picture is NEUTRAL with RSI(14) at 40. The 30-day range is $1.79 to $2.63, with near-term support at $2.07 and resistance at $2.45.
Century Therapeutics, Inc. Community Discussion
0Share your Century Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.